Tag: Baxdela

Unlike many other antibiotics in its class, delafloxacin possesses potent *in vitro* activity against a wide array of pathogens, including clinically relevant anaerobes. This article answers the crucial question: **Does delafloxacin cover anaerobes?** and explores the unique properties that give it a broader spectrum of coverage.

Approved by the FDA in 2017 for acute bacterial skin and skin structure infections (ABSSSI), delafloxacin is a novel fluoroquinolone antibiotic. Understanding **what does delafloxacin cover** is crucial, as its potent broad-spectrum activity, particularly against methicillin-resistant Staphylococcus aureus (MRSA), sets it apart from older agents in its class.

In a Phase 3 clinical trial for community-acquired bacterial pneumonia (CABP), delafloxacin demonstrated high rates of microbiological success against atypical pathogens. This confirms the answer to the question, 'Does delafloxacin cover atypicals?' and positions it as a valuable broad-spectrum antibiotic.